Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study

Erlene K. Seymour, MD, Yiwei Li, Amro Aboukameel, Radhakrishnan Ramchandren, Golbon Sterbis, Jay Yang, MD, Divaya Bhutani, MD, Ramzi Mohammad, PhD, Asfar Sohail Azmi, PhD, Jeff Zonder, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-140752

Published: 2020

Journal Articles

Bruton Tyrosine Kinase Inhibition in Classical Hodgkin Lymphoma Cell Lines and Animal Models

Irfana Muqbil, PhD, Amro Aboukameel, MS, Ramzi Mohammad, PhD, Asfar Sohail Azmi, PhD, Radhakrishnan Ramchandren, MD

Blood (2017) 130 (Supplement 1): 1536.

https://doi.org/10.1182/blood.V130.Suppl_1.1536.1536

Published: 2017

Journal Articles

Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo

Trinayan Kashyap, MS, Irfana Muqbil, Amro Aboukameel, Boris Klebanov, MA, MS, Ramzi Mohammad, PhD, Asfar Sohail Azmi, PhD, William Senapedis, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD PhD, Yosef Landesman, PhD

Blood (2016) 128 (22): 4131.

https://doi.org/10.1182/blood.V128.22.4131.4131

Published: 2016

Journal Articles

Development of a Novel Small Molecule CRM-1 Inhibitor for Non Hodgkin's Lymphoma

Asfar Sohail Azmi, Research Associate, Ayad Al-Katib, MD, FACP, Amro Aboukameel, RA, Michael Kauffman, MD, Ph.D., Dilara McCauley, Research Associate, Ramzi Mohammad, PhD, Sharon Shacham, PhD

Blood (2011) 118 (21): 598.

https://doi.org/10.1182/blood.V118.21.598.598

Published: 2011

Journal Articles

Superior Anti-Tumor Activity of the CD19-Directed Immunotoxin, SAR3419 to Rituximab in Non-Hodgkin’s Xenograft Animal Models: Preclinical Evaluation.

Amro Aboukameel, MS, Anton-Scott Goustin, PhD, Ramzi Mohammad, PhD, Claudia Zuany-Amorim, PhD, Marie-Christine Bissery, PhD, Ayad M. Al-Katib, MD

Blood (2007) 110 (11): 2339.

https://doi.org/10.1182/blood.V110.11.2339.2339

Published: 2007

NARROW

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study

Bruton Tyrosine Kinase Inhibition in Classical Hodgkin Lymphoma Cell Lines and Animal Models

Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo

Development of a Novel Small Molecule CRM-1 Inhibitor for Non Hodgkin's Lymphoma

Superior Anti-Tumor Activity of the CD19-Directed Immunotoxin, SAR3419 to Rituximab in Non-Hodgkin’s Xenograft Animal Models: Preclinical Evaluation.

Email alerts

ASH Publications

American Society of Hematology

Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study

Bruton Tyrosine Kinase Inhibition in Classical Hodgkin Lymphoma Cell Lines and Animal Models

Combination of Selinexor and the Proteasome Inhibitor, Bortezomib Shows Synergistic Cytotoxicity in Diffuse Large B-Cells Lymphoma Cells In Vitro and In Vivo

Development of a Novel Small Molecule CRM-1 Inhibitor for Non Hodgkin's Lymphoma

Superior Anti-Tumor Activity of the CD19-Directed Immunotoxin, SAR3419 to Rituximab in Non-Hodgkin’s Xenograft Animal Models: Preclinical Evaluation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only